Carotid artery stenting is safe and effective for symptomatic patients with acute coronary syndrome. Issue 1 (13th August 2019)

• Record Type: Journal Article
• Authors: Casana, Renato; Tolva, Valerio Stefano; Odero, Andrea; Malloggi, Chiara; Silani, Vincenzo; Parati, Gianfranco
• Is Part Of: Catheterization and cardiovascular interventions. Volume 96:Issue 1(2020)
• Page Start: 129
• Page End: 135
• Publication Date: 2019-08-13
• Subjects: acute myocardial infarction/STEMI -- carotid artery disease -- coronary artery disease -- percutaneous coronary intervention -- stenting technique; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.28445
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Background: Patients with symptomatic carotid stenosis recently treated with percutaneous transluminal coronary angioplasty (PTCA) for acute coronary syndrome (ACS) are always classified as at high risk for surgery, given that they are required uninterrupted dual antiplatelet therapy. In this regard, carotid artery stenting (CAS) may represent a valid alternative. Objective: The purpose of this study is to overview CAS outcomes in symptomatic patients with and without ACS. Methods: One hundred fifty‐one consecutive symptomatic patients who underwent CAS between 2010 and 2017 in a single institution were included in this study, of which 66 (43.7%) were identified as having ACS. All patients were followed‐up with carotid duplex ultrasound scan and a neurological assessment of symptoms status at 30‐day postprocedure and at 3, 6, and 12 months, with annual follow‐up after that for 3 years. Results: Among symptomatic ACS patients, common risks factors were active smoking, metabolic syndrome, diabetes, and hypertension. In the short‐term follow‐up, no significant differences were observed among rates of death, stroke, myocardial infarction (MI), and restenosis, between patients with and without ACS. Mean clinical follow‐up was 28.2 (12.3) months. In the long‐term follow‐up, higher rates of death and MI were recorded in patients with ACS (death: 11.4% vs. 5.4%, p = .04; MI: 11.4% vs. 3.6%, p = .02), owing to the complexity of these patients. Conclusions: This single‐center study suggested that CAS is a safe and effective treatment for patients with symptomatic carotid artery stenosis, who recently underwent PTCA for ACS, requiring uninterrupted dual antiplatelet therapy.